Transition in Leadership Marks New Era for Morphic Medical's Growth Strategy

Morphic Medical Announces CEO Transition

Morphic Medical, a pioneering company in the MedTech industry known for its groundbreaking work in minimally invasive treatments for obesity and related cardiometabolic disorders, has made a major announcement regarding its leadership. On August 5, 2025, the company disclosed that Joe Virgilio will transition out of his role as Chief Executive Officer after five impactful years, marking a significant change in the company's leadership and future direction.

During his tenure, Joe Virgilio has played an instrumental role in propelling Morphic Medical to new heights, overseeing critical milestones in product development, manufacturing, and overall organizational growth. Notably, he led efforts that resulted in the regulatory approval for RESET®, a novel device designed to address morbid obesity and its associated risks. This significant achievement highlights the forward momentum that Morphic Medical has experienced under Virgilio's guidance.

The Board of Directors has appointed Mike Gutteridge as the new CEO, who brings a wealth of experience from his previous roles including Vice President of Therapy Development and Commercial Operations at Morphic. Gutteridge has been pivotal in shaping the go-to-market strategy for RESET® and is expected to steer the company into its next chapter of growth.

Mark Lerdal, Chair of the Board, expressed gratitude for Virgilio's leadership, acknowledging his vision and commitment to both innovation and patient care. Lerdal stated, "Joe has been instrumental in shaping Morphic Medical into the company it is today. We are grateful for his vision, leadership, and commitment to innovation and patient care. We are equally excited to welcome Mike, who shares our values and brings a successful track record of international commercialization as we enter our next phase of growth."

Virgilio reflected on his time at Morphic Medical, stating, "It has been a privilege to lead Morphic Medical over the past five years. I am proud of what our tremendous team has accomplished and am confident in the company's future under Mike. I remain committed to the mission and look forward to supporting Mike and the Board as Morphic transitions into this exciting next chapter."

On taking the helm, Gutteridge expressed his honor in succeeding Virgilio. He stated, "With over 30 years in the medtech sector spanning clinical innovation, commercial strategy, market development and reimbursement, I am energized by the opportunity to lead Morphic into its next phase. This will involve a focused expansion into global markets, accelerated commercialization, and a deepening of our commitment to improving the lives of patients through effective durable therapies."

As CEO, Gutteridge vows to build upon Morphic's pioneering work in gastrointestinal (GI) metabolic health. He aims to foster a culture of agility and partnership within the company and with its growing network of clinicians and investors. His vision includes ensuring that Morphic's innovative technology reaches those in need while generating sustainable value through responsible growth.

This transition in leadership highlights a carefully orchestrated approach to maintaining continuity across operations, stakeholders, and partnerships, ensuring that Morphic Medical remains a forerunner in the MedTech field.

Founded in 2003 and headquartered in Boston, Massachusetts, Morphic Medical continues to develop pioneering solutions for obese patients and those struggling with cardiometabolic disorders. Their flagship product, RESET, is designed as a non-surgical alternative for morbid obesity, although it is currently limited to investigational use in the United States.

As the company looks ahead, it is clear that Morphic Medical is primed for an exciting evolution under new leadership, focusing on addressing critical health challenges faced by millions worldwide. The leadership transition not only reflects Morphic Medical's adaptability but also its vision to innovate and expand its impact within the MedTech landscape.